OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
April 14, 2021
The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?
April 13, 2021
More capital gains and the potential strains for rest of 2021.
March 18, 2021
Report provides comprehensive look at financial and accounting issues faced by life sciences industry.
March 11, 2021
Examining the key biopharma stock numbers and industry trends from a year that challenged the conduct of business and market stability like never before.
Amid vaccine heroics, its complex story may finally be resonating.
February 11, 2021
Dueling paths leave market fortunes uncertain.
January 08, 2021
Tone still set on the market catalysts to look for in 2021.
December 11, 2020
Vaccine strides, likely pricing impasse point to optimism for 2021.
November 16, 2020
Chief financial officers gather virtually to share the stories of directing their company IPOs over the finish line amid the COVID-19 pandemic.
Biopharma raises an unprecedented $100 billion.